The Role of Homocysteine in End‐Stage Renal Disease

This publication has 39 references indexed in Scilit:

• VI. Causes of death
  American Journal of Kidney Diseases, 1996
• Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
  Atherosclerosis, 1996
• Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients
  Atherosclerosis, 1996
• High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
  Kidney International, 1996
• A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
  Nature Genetics, 1995
• Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure?
  The Netherlands Journal of Medicine, 1995
• Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation
  Atherosclerosis, 1995
• Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease
  New England Journal of Medicine, 1991
• Heterozygosity for Homocystinuria in Premature Peripheral and Cerebral Occlusive Arterial Disease
  New England Journal of Medicine, 1985
• Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine‐homocysteine mixed disulphide
  European Journal of Clinical Investigation, 1979